Combined doxorubicin and cyclophosphamide chemotherapy for nonresectable feline fibrosarcoma.
A retrospective evaluation was performed on 12 cats with nonresectable, histopathologically confirmed fibrosarcomas that were treated with doxorubicin and cyclophosphamide chemotherapy. All of the tumors were located in sites potentially used for vaccination. Six cats had a greater than 50% decrease in gross tumor burden. However, the responses were not durable, with a median response duration of 125 days. All cats developed progressive disease. When animals that received other treatments after doxorubicin-based chemotherapy were eliminated from the analysis, median survival time was significantly longer for cats that responded to chemotherapy compared with the median survival time for nonresponders (242 and 83 days, respectively). These findings may serve as a basis for further evaluating the role of chemotherapy in the treatment of vaccine-associated sarcomas.
Barber
L G
LG
Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia 19104-6010, USA.
Sørenmo
K U
KU
Cronin
K L
KL
Shofer
F S
FS
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002415:Cats; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D011996:Records / Q000662:veterinary; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000139:chemically induced / Q000188:drug therapy / Q000662:veterinary*; D016896:Treatment Outcome; D014612:Vaccines / Q000009:adverse effects
D014612:Vaccines; D004317:Doxorubicin; D003520:Cyclophosphamide